In a recent post on the FDA Voice blog, the Agency reported that its generic drug program hit record highs in 2016. In the blog post, Kathleen “Cook” Uhl, M.D., Director of FDA’s Office of Generic Drugs (OGD), states that “the timing couldn’t be better amid concerns about rising drug prices.”
The following are important to note about this advancement:
To read the full story, view FDA’s blog post. For additional details and data related to OGD’s 2016 performance, view the Agency’s annual report.
Are you in the process of developing a generic drug? Are you seeking FDA-approval of a generic product? Using our proprietary approach to FDA, we can help with these or any other FDA-related matters. To learn more about our services and how we can help you, contact us today.
October 5, 2016
On Wednesday, September 28th, the FDA issued a final guidance document regarding the inclusion of the term “healthy” on the labels of food products. The guidance, entitled “Use of the Term ‘Healthy’...
February 16, 2016
Last week, we provided you with details on FDA’s recommendations for describing display devices in 510(k) premarket submissions. Did we leave you wanting more? Well if you were wishing for additional...
August 9, 2016
Late last month, FDA released a warning letter that had been sent to Xiamen Pharmaceutical Co., Ltd., outlining a number of “significant deviations from current good manufacturing practice (CGMP) for...